In the BioHarmony Drug Report Database
Alitretinoin
Panretin (alitretinoin) is a small molecule pharmaceutical. Alitretinoin was first approved as Panretin on 1999-02-02. It is used to treat kaposi sarcoma and skin diseases in the USA. The pharmaceutical is active against retinoic acid receptor alpha, vitamin K epoxide reductase complex subunit 1, retinoic acid receptor beta, and retinoic acid receptor gamma. In addition, it is known to target retinoic acid receptor RXR-alpha, retinoic acid receptor RXR-gamma, retinoic acid receptor RXR-beta, and thyroid hormone receptor alpha.
Trade Name
|
Panretin |
|---|---|
Common Name
|
alitretinoin |
ChEMBL ID
|
CHEMBL705 |
Indication
|
kaposi sarcoma, skin diseases |
Drug Class
|
Retinol derivatives |
Image (chem structure or protein)